- In a regulatory filing, Zosano Pharma (NASDAQ:ZSAN) discloses that Novo Nordisk (NYSE:NVO) notified it that it will terminate their January 2014 collaboration to develop transdermal formulations of Novo's glucagon-like peptide (GLP-1) analogues. Novo's decision is based on its desire to focus on other priorities in its research portfolio. Once the agreement ends, all technology rights licensed to Novo will revert back to Zosano.
- There has been no after hours trading in ZSAN shares yet.